Natera, Inc. NTRA
Note: A glossary of terms used in this Form 10-K appears at the end of this Item 1. 10-K, Item 1
- Headquarters
- Austin, TX
- CEO
- Steven Leonard Chapman
- Next results
- around Jan 11, 2027
NTRA among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
8 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 27, 2026 against Feb 28, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 9 checks found nothing to note
-
Inventory growing faster than revenueInventory +53.0% ($44.7M to $68.4M) vs revenue +35.9% ($1.7B to $2.3B), +17.1 pts apart
-
Critical audit matters changedNew this year: Valuation of Developed Technology Intangible Asset Acquired in a Business Combination (“As described in Note 3 to the consolidated financial statements, on December 4, 2025, the Company completed its acquisition of Foresight Diagnostics, Inc. (“Foresight Diagnostics”). The transaction was accounted for as a business combination using the acquisition method of accounting. The acquisitio”). Same as last year: Product Revenue
-
Receivables -5.6% ($314.2M to $296.5M) vs revenue +35.9% ($1.7B to $2.3B), -41.5 pts apart
8 more checks with nothing to note
-
Cash from operations $215.3M vs net income −$208.2M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
8 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
We are incorporating artificial intelligence across various areas of our business, which presents risks that could adversely affect our business and results of operations. We are incorporating artificial intelligence, or AI, and machine learning, or ML, technologies into aspects of our business. The development and use of these…
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
We may not be able to obtain approval from the FDA for Signatera PMAs currently under review or for applications that we may submit to FDA in the future. We have submitted PMAs for Signatera for approval as a companion diagnostic. We may face difficulties in obtaining approval of these PMAs for a variety of reasons, including failure to…
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
Moreover, our clinical trials to support PMA approval must be conducted under an FDA-approved IDE. FDA has the authority to deny IDE submissions, or to suspend or revoke IDEs once granted, under certain conditions, including noncompliance with FDA requirements or undue risks to subjects. If we are unable to maintain our current IDEs or…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $820.2M | $1.1B | $1.7B | $2.3B |
| Net income | −$547.8M | −$434.8M | −$190.4M | −$208.2M |
| Operating cash flow | −$431.5M | −$247.0M | $135.7M | $215.3M |
| Free cash flow | −$479.2M | −$286.2M | $69.2M | $109.1M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.3B ▲ 35.9% in FY2025−$208.2M in FY2025$109.1M ▲ 57.6% in FY2025
Recent filings
32 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 5, 2026Roy Baynes (member of the Company's board of directors) adopted a 10b5-1 trading plan reported in the 10-Q
-
Planned saleNov 5, 2026Daniel Rabinowitz (chief legal officer and secretary) adopted a 10b5-1 trading plan reported in the 10-Q, up to 60,000 shares
-
Planned saleNov 5, 2026John Fesko (chief business officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 90,000 shares, runs to Dec 31, 2027
-
Planned saleNov 5, 2026Matthew Rabinowitz (executive chairman) adopted a 10b5-1 trading plan reported in the 10-Q, up to 200,000 shares
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
About the company
Natera, Inc., Austin, TX · from the 10-K filed Feb 27, 2026
Note: A glossary of terms used in this Form 10-K appears at the end of this Item 1. We are a diagnostics company with proprietary molecular and bioinformatics technology that we are applying to change disease management worldwide. Our cell-free DNA, or cfDNA, technology combines our novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with our statistical algorithms that incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage.
- Headquarters
- Austin, TX
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NTRA/export.csv") into a cell.